SCHEMBL21747402

SCHEMBL21747402

COc1cccc(-c2cccn2C2(C(=O)C(C(=O)O)C(=O)O)CCCC2)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RECQL P46063 1/20 0.38
LMNA P02545 2/20 0.37
NR1H2 P55055 1/20 0.37
NR1H3 Q13133 1/20 0.37
AKR1C3 P42330 1/20 0.37
AKR1C2 P52895 1/20 0.37
SLC16A3 O15427 2/20 0.37
SLC16A1 P53985 2/20 0.37
MCTS1 Q9ULC4 1/20 0.37
JAK2 O60674 1/20 0.37
ALDH1A1 P00352 3/20 0.36
HPGD P15428 3/20 0.36
GPR35 Q9HC97 1/20 0.36
TSHR P16473 1/20 0.36
MAPK1 P28482 1/20 0.36
HTR1A P08908 1/20 0.36
DRD2 P14416 1/20 0.36
HTR2A P28223 1/20 0.36
HTR7 P34969 1/20 0.36
HTR6 P50406 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21765700 0.90 JAK2 (0.38) RECQLLMNAJAK2ALDH1A1HPGD
SCHEMBL25544144 0.89 CHRNA1 (0.38) RECQLNR1H2NR1H3AKR1C3AKR1C2
SCHEMBL21747267 0.88 ALDH1A1 (0.37) LMNAALDH1A1HPGDKDM4EMAPT
SCHEMBL21747276 0.88 ALDH1A1 (0.42) RECQLNR1H2NR1H3SLC16A3SLC16A1
SCHEMBL21747378 0.87 FAAH (0.39) LMNAALDH1A1HPGDTSHRKDM4E
SCHEMBL21747421 0.84 EGLN1 (0.37) RECQLALDH1A1TSHRKDM4E
SCHEMBL21747280 0.82 EGLN1 (0.37) LMNAALDH1A1TSHRKDM4ESMN1; SMN2
SCHEMBL21747367 0.81 EGLN1 (0.37) RECQLALDH1A1TSHRKDM4EMAPT
SCHEMBL21747395 0.79 EGLN1 (0.37) ALDH1A1MAPK1KDM4EMAPT
SCHEMBL21747383 0.78 EGLN1 (0.35) ALDH1A1KDM4EMAPTPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11970495-B2 Indolizine derivatives and their application in medicine KIND PHARMACEUTICAL (CN) 2024-04-30 US disclosed
US-11945817-B2 Indolizine derivatives and their application in medicine KIND PHARMACEUTICAL (CN) 2024-04-02 US disclosed
US-20230257379-A1 INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE KIND PHARMACEUTICAL (CN) 2023-08-17 US disclosed
US-20230242527-A1 INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE KIND PHARMACEUTICAL (CN) 2023-08-03 US disclosed
US-11655249-B2 Indolizine derivatives and their application in medicine KIND PHARMACEUTICAL (CN) 2023-05-23 US disclosed
EP-3613742-B1 INDOLIZINE DERIVATIVES AND APPLICATION THEREOF IN MEDICINE KIND PHARMACEUTICAL (CN) 2022-12-07 EP disclosed
US-20210253570-A1 INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE KIND PHARMACEUTICAL (CN) 2021-08-19 US disclosed
US-11021478-B2 Indolizine derivatives and their application in medicine KIND PHARMACEUTICAL (CN) 2021-06-01 US disclosed
US-20200165242-A1 INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE KIND PHARMACEUTICAL (CN) 2020-05-28 US disclosed
EP-3613742-A1 INDOLIZINE DERIVATIVES AND APPLICATION THEREOF IN MEDICINE Kind Pharmaceutical (CN) 2020-02-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230257379-A1 INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE INMT, IDO1, IDO2 RECQL 4355/4885LMNA 2594/4885NR1H2 675/4885
US-11021478-B2 Indolizine derivatives and their application in medicine INMT, IDO1, IDO2 RECQL 4355/4885LMNA 2594/4885NR1H2 675/4885
US-11970495-B2 Indolizine derivatives and their application in medicine INMT, IDO1, IDO2 RECQL 4355/4885LMNA 2594/4885NR1H2 675/4885
US-20230242527-A1 INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE INMT, IDO1, IDO2 RECQL 4355/4885LMNA 2594/4885NR1H2 675/4885
US-11945817-B2 Indolizine derivatives and their application in medicine INMT, IDO1, IDO2 RECQL 4355/4885LMNA 2594/4885NR1H2 675/4885
US-20210253570-A1 INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE INMT, IDO1, IDO2 RECQL 4355/4885LMNA 2594/4885NR1H2 675/4885
US-11655249-B2 Indolizine derivatives and their application in medicine INMT, IDO1, IDO2 RECQL 4355/4885LMNA 2594/4885NR1H2 675/4885
US-20200165242-A1 INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE INMT, IDO1, IDO2 RECQL 4355/4885LMNA 2594/4885NR1H2 675/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.